1.38
+2.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ProQR Therapeutics
Its shares trade under the ticker PRQR. It has been listed since 18 September 2014. In the fiscal year to 31 December 2025, it reported revenue of €15.3m and a net loss of €40.5m. At that date it held total assets of €132.4m and shareholders' equity of €58.0m.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Sept 2014
- Employees
- 187
- Website
- proqr.com ↗
- Head office
- ZERNIKEDREEF 9, LEIDEN
- Incorporated in
- P7
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. James ShannonIndependent Non-Executive Chairman of the Board€122,000
- Mr. Daniel de BoerChief Executive Officer, Founder, Executive Director, since 2012€1.8m
- Mr. Dennis HomChief Financial Officer
- Ms. Sheila SponseleeChief People and Operations Officer
- Mr. Gerard PlatenburgChief Scientific Officer, Executive Director, since 2014€488,000
- Mr. Rene BeukemaChief Corporate Development Officer, General Counsel, Executive Director€980,000
- Dr. Cristina LopezChief Medical Officer
- Ms. Theresa HeggieNon-Executive Director, since 2019€175,000
- Mr. Dinko ValerioNon-Executive Director, since 2014€107,000
- Ms. Begona CarrenoNon-Executive Independent Director€77,000
- Mr. Bart FiliusNon-Executive Independent Director€100,000
- Ms. Alison LawtonNon-Executive Independent Director€99,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 62
- Social
- 99
- Governance
- 25
- Women in the workforce
- 62%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ProQR Therapeutics NV has several strengths that contribute to its success in the biopharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, ProQR Therapeutics NV also faces certain weaknesses that can pose challenges to its growth and competitiveness:
Opportunities
- ProQR Therapeutics NV can leverage various opportunities in the market to enhance its growth and market position:
Threats
- ProQR Therapeutics NV faces certain threats that could impact its business operations and market performance:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.